PMID: 8580899Sep 1, 1995Paper

Deficient antipneumococcal polysaccharide responses in HIV-seropositive patients

FEMS Immunology and Medical Microbiology
A E LoeligerJ C Borleffs

Abstract

In a prospective study, serological responses and opsonic activity towards Streptococcus pneumoniae were measured in 60 HIV-infected patients and 25 controls after the administration of the 23-valent pneumococcal vaccine (PneumovaxR). Serum samples were collected before vaccination and at weeks 1, 2, 4, and 12 after vaccination and were tested for the presence of antibodies against a mixture of capsular polysaccharide antigens (pool) and against type 3 and type 4 antigens (PS3 and PS4), using an ELISA. A serological response was defined as a two-fold or greater increase in serum titer after vaccination. Opsonophagocytosis was measured in patients with a definite response against PS3. Generally, prevaccination antipneumococcal antibody titers were clearly higher in HIV-infected patients than in healthy controls. After vaccination, antipool antibody responses were found in 76% of vaccinated patients; 24% of the patients were non-responders. In patients with more than 0.300 x 10(9) CD4 + cells per liter the percentage of responders was 94%; in patients with fewer than 0.300 x 10(9) CD4 + cells per liter this percentage was 68% (P < 0.05). The antipool response in control subjects was 92%. A serological response to PS3 and PS4 was ...Continue Reading

References

Aug 31, 1978·The New England Journal of Medicine·G R SiberG Schiffman
Aug 1, 1977·The Journal of Infectious Diseases·D E MosierW E Paul
Jan 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M C Rodriguez BarradasC V Sanders
Aug 15, 1992·Annals of Internal Medicine·E N JanoffP C Hopewell
May 1, 1991·The American Journal of Medicine·W A SchwartzmanM B Goetz
Nov 1, 1991·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G A Bruyn, R van Furth
Nov 21, 1991·The New England Journal of Medicine·E D ShapiroJ D Clemens
Jan 1, 1989·The Pediatric Infectious Disease Journal·J O Klein
Jul 15, 1988·Annals of Internal Medicine·A C CollierH H Handsfield
Jan 1, 1986·Annals of Internal Medicine·B PolskyD Armstrong
Apr 17, 1987·JAMA : the Journal of the American Medical Association·K L HuangM Ho
Dec 1, 1987·The Journal of Infectious Diseases·C L CelumD F Echenberg
Apr 17, 1986·Journal of Immunological Methods·G T Rijkers
Jun 1, 1973·The Journal of Experimental Medicine·P J BakerB Prescott
Apr 1, 1983·The Journal of Clinical Investigation·J H Kehrl, A S Fauci
Mar 16, 1984·JAMA : the Journal of the American Medical Association·A J AmmannM Conant
Nov 1, 1981·Archives of Internal Medicine·C C LinnemannG Schiffman
Sep 1, 1980·The American Journal of Medicine·H M LazarusH M Rodman
Aug 1, 1982·Immunology Today·D E Mosier, B Subbarao

❮ Previous
Next ❯

Citations

Aug 1, 1997·AIDS Patient Care and STDs·T L Katzenstein
Sep 5, 2006·Journal of Clinical Pathology·Paul BalmerRay Borrow
Jun 29, 2004·The Lancet Infectious Diseases·Daniel R FeikinEdward N Janoff
Dec 9, 2014·Human Vaccines & Immunotherapeutics·Kuan-Yeh LeeChien-Ching Hung
Aug 30, 2016·HIV Medicine·Anna Maria GerettiAlison Rodger
Apr 29, 2009·Current Opinion in Pulmonary Medicine·Giordano MadedduMaria Stella Mura
Feb 11, 1998·Clinical Microbiology Reviews·L A Pirofski, A Casadevall
Feb 3, 2004·Immunology and Allergy Clinics of North America·David J Weber, William A Rutala

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.